Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study

To evaluate the efficacy of atezolizumab plus bevacizumab treatment in patients with hepatocellular carcinoma (HCC) previously treated with molecular targeted agents (MTAs). Thirty-one patients treated with atezolizumab plus bevacizumab for unresectable HCC and previously treated with MTAs were enro...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugimoto, Rie, Satoh, Takeaki, Ueda, Akihiro, Senju, Takeshi, Tanaka, Yuki, Yamashita, Shinsaku, Koyanagi, Toshimasa, Kurashige, Tomoyuki, Higuchi, Nobito, Nakamura, Tsukasa, Tanaka, Masatake, Azuma, Yuuki, Ohno, Akari, Ooho, Aritsune, Ooe, Mari, Mutsuki, Taiji, Uchimura, Koutarou, Kuniyoshi, Masami, Tada, Seiya, Aratake, Yoshifusa, Yoshimoto, Tsuyoshi, Yamashita, Naoki, Harada, Shigeru, Nakamuta, Makoto, Motomura, Kenta, Kohjima, Motoyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542563/
https://www.ncbi.nlm.nih.gov/pubmed/36221372
http://dx.doi.org/10.1097/MD.0000000000030871

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542563/
https://www.ncbi.nlm.nih.gov/pubmed/36221372
http://dx.doi.org/10.1097/MD.0000000000030871

Ejemplares similares